NCT00631800View on ClinicalTrials.gov

Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

November 30, 2004

Conditions
Staphylococcal Sepsis
Interventions
DRUG

Pagibaximab (formerly BSYX-A110)

Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14

Trial Locations (1)

77030

Texas Children's Hospital/Ben Taub Hospital (Baylor College of Medicine), Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Biosynexus Incorporated

INDUSTRY

NCT00631800 - Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110 | Biotech Hunter | Biotech Hunter